DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

(2014) Angelo Avogaro et al.   Current Diabetes Reports

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

(2014) Ravi Nistala et al.   Obesity

Linagliptin: from bench to bedside

(2014) John Doupis   Drug Design Development and Therapy

Effect of Strict Glycemic Control in Patients With Diabetes Mellitus on Frequency of Macrovascular Events

(2013) Amita Singh et al.   AMERICAN JOURNAL OF CARDIOLOGY

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

(2013) Derek J Hausenloy et al.   Cardiovascular Diabetology

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

(2013) Yuji Ishibashi et al.   Cardiovascular Diabetology

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

(2013) Maximilian von Eynatten et al.   Cardiovascular Diabetology

Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats

(2013) Annayya R. Aroor et al.   ENDOCRINOLOGY

Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension

(2013) Lyubov Chaykovska et al.   JOURNAL OF HYPERTENSION

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long‐Term Renal Denervation Normalizes Disrupted Blood Pressure Circadian Rhythm and Ameliorates Cardiovascular Injury in a Rat Model of Metabolic Syndrome

(2013) Tetsuji Katayama et al.   Journal of the American Heart Association

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

(2013) Baptist Gallwitz   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus

(2012) Harshal R. Patil et al.   AMERICAN JOURNAL OF CARDIOLOGY

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease

(2012) Jixin Zhong et al.   ATHEROSCLEROSIS

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

(2012) Swenja Kröller-Schön et al.   CARDIOVASCULAR RESEARCH

Increased Expression of NAD(P)H Oxidase Subunit p67phox in the Renal Medulla Contributes to Excess Oxidative Stress and Salt-Sensitive Hypertension

(2012) Di Feng et al.   Cell Metabolism

Recent advances in incretin-based therapies

(2012) David Russell-Jones et al.   CLINICAL ENDOCRINOLOGY

Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease

(2012) Usha Panchapakesan et al.   CLINICAL SCIENCE

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

(2012) Limei Liu et al.   HYPERTENSION

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

(2011) Ilaria Dicembrini et al.   Experimental Diabetes Research

Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats

(2011) Taishi Nakamura et al.   HYPERTENSION RESEARCH

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

(2010) Que Liu et al.   Cardiovascular Diabetology

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

(2010) Annis Marney et al.   HYPERTENSION

Apoptosis signal-regulating kinase 1 deficiency eliminates cardiovascular injuries induced by high-salt diet

(2010) Keiichiro Kataoka et al.   JOURNAL OF HYPERTENSION

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

(2010) Bruna PM Pacheco et al.   JOURNAL OF HYPERTENSION

Genetic and dietary salt contributors to insulin resistance in Dahl salt-sensitive (S) rats

(2008) Marlene F Shehata   Cardiovascular Diabetology

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE

(2007) Edwin K Jackson et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With Candesartan

(2007) Taishi Nakamura et al.   HYPERTENSION